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Abstract
Background: Extranodal NK/T-cell lymphoma, nasal type (ENKTL) is not common worldwide, but it is the most
common T- and NK-cell lymphomas in many Asian countries. Immunophenotypic profiles were studied based on
limited series. The authors, therefore, studied on ENKTL according to characterize immunophenotypic profiles as
well as the distribution of EBV subtype and LMP-1 gene deletion.
Methods: By using tissue microarray (TMA), immunohistochemical study and EBV encoded RNA (EBER) in situ
hybridization were performed. T-cell receptor (TCR) gene rearrangement, EBV subtyping, and LMP-1 gene deletion
were studied on the available cases.
Results: There were 22 cases eligible for TMA. ENKTL were positive for CD3 (91%), CD5 (9%), CD7 (32%), CD4
(14%), CD56 (82%), TIA-1 (100%), granzyme B (95%), perforin (86%), CD45 (83%), CD30 (75%), Oct2 (25%), and IRF4/
MUM1 (33%). None of them was positive for bF1, CD8, or CD57. TCR gene rearrangement was negative in all 18
tested cases. EBV was subtype A in all 15 tested cases, with 87% deleted LMP-1 gene. Cases lacking perforin
expression demonstrated a significantly poorer survival outcome (p = 0.008).
Conclusions: The present study demonstrated TIA-1 and EBER as the two most sensitive markers. There were a
few CD3 and/or CD56 negative cases noted. Interestingly, losses of CD45 and/or CD7 were not uncommon while
Oct2 and IRF4/MUM1 could be positive in a subset of cases. Based on the present study in conjunction with the
literature review, determination of PCR-based TCR gene rearrangement analysis might not be a useful technique
for making diagnosis of ENKTL.
Keywords: Extranodal NK/T-cell lymphoma, pathology, immunophenotype, EBV, LMP-1 gene, TCR gene
rearrangement
Background
T-cell lymphoma, especially extranodal NK/T-cell lym-
phoma, nasal type (ENKTL), has a higher incidence in
Asian and Latin American countries than the Western
[1-3]. In a recently published series of 71 consecutive
mature T- and NK-cell lymphomas in Thailand, ENKTL
accounted for 31%, the most common subtype which is
higher than other types including anaplastic large cell
lymphoma (18%), angioimmunoblastic T-cell lymphoma
(14%), peripheral T-cell lymphoma, not otherwise speci-
fied (PTCL, NOS, 13%), and other less common sub-
types [4].
ENKTL is a type of non-Hodgkin lymphoma, most
common in upper aerodigestive tract, particularly nasal
cavity [2,3,5]. ENKTL is believed to be derived from
either NK- or cytotoxic T-cell, but the former is more
common [5,6]. T-cell receptor (TCR) gene rearrange-
ment is mostly in germ line configuration, correspond-
ing to the majority of cases those are of NK-cell lineage
[6,7]. Due to the different therapeutic approach and
prognostic outcome of ENKTL from other T-cell/NK-
cell lymphomas, definite diagnosis for appropriate
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needs a different therapeutic approach, but only limited
series studied on expanded phenotypic features which
important for distinguishing ENKTL from other T-cell
lymphomas.
Epstein-Barr virus (EBV) is closely associated with
E N K T L[ 1 , 2 ] .I th a sAo rBs u b t y p e sa sd e t e r m i n e db y
the difference of EBV nuclear antigen 2 (EBNA2) gene
sequence [2,9]. And almost all cases of Asian ENKTL
are subtype A [2,5,6,10-12], while a Europe, North
America and Latin America have variable proportions of
subtype B [13-19]. Nevertheless, no EBV subtype has
been documented in Thai ENKTL before.
The present study was focused on basic clinical infor-
mation, histopathology, immunophenotype, and PCR-
based TCR gene rearrangement. EBV subtype and EBV
LMP-1 gene deletion were also of interest.
Methods
This study was approved by the Institutional Review
Board, Faculty of Medicine Siriraj Hospital, Mahidol
University (Si087/2008).
The study samples were newly diagnosed ENKTL dur-
ing 2004 and 2007 at Department of Pathology, Siriraj
Hospital. Known cases of ENKTL, consultation cases
from other hospitals without patient visit at Siriraj Hos-
pital, and cases with inadequate material for a making
definite diagnosis were excluded.
Basic clinical features, histopathologic,
immunophenotypic, and in situ hybridization studies
All newly diagnosed cases of extranodal lymphoma of
either T- or NK type of head and neck region were
recruited for review. Clinical information was gathered
from those given in the requisitions and medical
records. Histopathologic features were reviewed by TP
and SS, and partially by DN and KO. The criteria for
diagnosis were based on the “WHO Classification of
Tumours of Haematopoietic and Lymphoid tissues”
published in 2008 [1].
For the cytomorphological aspect, using nuclear size,
we divided cases into 6 categories: 1) small, for predo-
minantly small cells (>75% of lymphoma cells); 2) small
to medium, for mixture of small to medium-sized cells
(at least 25% each); 3) predominantly medium, for pre-
dominantly medium-sized cells (>75% of cells); 4) med-
ium to large, for mixture of medium-sized to large cells
(at least 25% each); 5) large, for predominantly large
cells (>75% of cells); and 6) anaplastic, for a fair amount
of anaplastic cell component (at least 25% of cells). In
the present study, small cell means cell which had
nuclear size similar to a normal lymphocyte; large cell
had nuclear size equal or greater than the twice size of
a normal lymphocyte; medium-sized cell had nucleus
intermediate between small and large cell; and anaplastic
cell was large cell with anaplastic features.
A tissue microarray (TMA) block was constructed
from formalin-fixed paraffin-embedded (FFPE) tissue
(3.5 mm thick cores). The antibodies for immunohisto-
chemical studies included ALK (ALK1, dilution 1:100),
BCL2 (124, 1:50), BCL6 (LN22, 1:100), bF1 (8A3, 1:20),
CD1a (010, 1:200), CD3 (LN10, 1:600), CD4 (4B12,
1:10), CD5 (4C7, 1:100), CD7 (CBC.37, ready to use),
CD8 (C8/144B, ready to use), CD10 (56C6, ready to
use), CD15 (MMA, 1:200), CD20 (L26, 1:2,000), CD23
(1B12, 1:100), CD30 (Ber-H2, 1:100), CD34 (M7165,
1:300), CD43 (DF-T1, 1:500), CD45 (LCA, 1:1,500),
CD56 (123C3.D5, 1:50), CD57 (TB01, 1:300), CD79a
(JCB117, 1:600), CD117 (c-kit, 1:5,000), CD138 (MI15,
1:1,000), cyclinD1 (SP4, 1:200), Interferon regulatory fac-
tor-4/Multiple myeloma-1 (IRF4/MUM1) (MUM1p,
1:800), granzyme B (GrB-7, 1:50), BOB.1 (TG14, 1:20),
Oct2 (C-20, 1:4,000), perforin (5B10, 1:150), PAX5 (24,
ready to use), TIA-1 (TIA-1, 1:500), and TdT (SEN28,
1:100). The immunohistochemical studies and EBV-
encoded RNA (EBER) in situ hybridization were per-
formed in an automated staining machine (Benchmark
®
XT). Criteria for interpretation of immunohistochemis-
try and EBER in situ hybridization were as follows: 1)
mostly positive - definitelyp o s i t i v eo nl y m p h o m ac e l l s
>50%, 2) partially positive -10-50% positive staining, 3)
probably negative - <10% staining on presumptive lym-
phoma cells, and 4) clearly negative -clearly negative.
Morphologic and immunophenotypic analyses were
based on only cases with adequate tissue in TMA block.
T-cell receptor gene rearrangement molecular studies
Only cases with adequate tissue on TMA slides were
subjected to PCR-based TCR gene rearrangement analy-
sis. Twenty serial 10-μm-thick sections of tissue from
FFPE tissue were obtained for molecular genetic studies.
The PCR primer sequences were designed following
BIOMED-2 protocols [20], which the present study
included primers for TCRg, δ and b genes, and using
the previously reported method [21].
PCR analysis for EBV subtype and LMP-1 deletion
Only cases with adequate tissue on TMA slides were
subjected to EBV molecular genetic analysis. After the
tissue sectioning for TCR gene rearrangement, the
representative tissues from FFPE blocks of each case
were sent to study at The Department of Pathology,
Kurume University School of Medicine, Japan. The
DNA preparation was performed from whole sections of
the 22 ENKTL cases. DNA samples were extracted
using a commercial kit (Blood & Tissue Genomic
Extraction Miniprep System
®, Viogene). The extracted
DNA was used for PCR.
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typing, previously reported by Ohshima et al [22], were
used for DNA amplification (listed in Table 1). The final
reaction was incubated at 95°C for 10 min, followed by
50 cycles of 95°C for 30 s, 60°C for 30 s, and 72°C for
30 s. Then, a final extension at 72°C for 10 minutes was
performed.
After DNA amplification, the amplified products were
subjected to electrophoresis in 3% agarose gel, and were
visualized by ethidium bromide staining under ultravio-
let light. The expected sizes of EBV type A (EBNA 2A)
and B (EBNA 2B) products were 116 and 120 bp in
length, respectively.
To test for a 30 bp LMP-1 gene deletion at nucleotide
positions of 168, 256-168, and 285, the B95-8 (wild
type) EBV gene was used for comparison [23]. Primers
(LMP-1-A, LMP-1-B) flanking the characteristic 30 bp
deletion were synthesized (Table 1). The condition for
DNA amplification and detection of PCR products were
the same as for EBV subtyping. The expected PCR pro-
ducts of wild and deletion types were 210 and 180 bp,
respectively.
The genomic locus of b-actin was used as an internal
control. The semi- nested PCR reaction consisted as fol-
lows: after initial denaturation at 95°C for 10 min, 5
cycles of 95°C for 30 s, 63°C for 30 s, and 72°C for 30 s;
followed by 45 cycles of 95°C for 30 s, 60°C for 30 s,
and 72°C for 30 s, and then with a final extension at 72°
C for 10 min. The expected size of genomic b-actin was
148 bp.
Clinical course
In cases with adequate tissue in TMA, additional clinical
data including Ann Arbor stage, international prognostic
index (IPI) score, modes of treatment, and survival sta-
tus was collected. The Kaplan-Meier survival analyses
were performed based on various factors.
Statistical Evaluation
Statistical comparisons between characters were per-
formed using the 2-tailed Fisher exact test (SPSS, v.
1 8 . 0 ,C h i c a g o ,I L ) .L o gR a n kt e s t( S P S S ,v .1 8 . 0 )w a s
used for determination of the differences in survival out-
come. Statistical significant was defined if p < 0.05.
Results
There were 31 cases of newly diagnosed ENKTL
recruited over the 4-year period. Of the 31 cases, 5
cases of nasal biopsy and 1 case of pharyngeal biopsy
had not enough tissue left on paraffin block for further
studies. Thus, 25 cases were constructed in a TMA
block, but 3 of them were cut through the neoplastic
parts which inadequate for interpretation. Therefore,
only 22 cases of ENKTL were subjected to immunophe-
notypic and TCR gene rearrangement studies.
Basic clinical features
In term of geographic distribution, the patients came
from all regions of Thailand, 14 cases (45%) from cen-
tral region, 11 cases (36%) from Bangkok Metropolitan
and periphery, 3 cases (10%) from northeastern region,
2 cases (7%) from southern region, and 1 case (3%)
from northern region.
For sites of lymphoma at presentation, 16 cases (52%)
had nasal cavity involvement, 1 case (3%) with bone
marrow and nasal cavity, 1 case (3%) with nasal cavity
and sinuses, 1 case (3%) with nasal and oral cavities, 3
cases (10%) with nasal cavity and nasopharynx, 3 cases
(10%) with nasopharynx, 2 cases (7%) with oral cavity
(palate and buccal mucosa each), 2 cases (7%) with peri-
orbital tissue, 1 case (3%) with pharynx, and 1 case (3%)
with larynx and base of tongue. Among these cases,
there were 2 out of 27 patients (7%, case no. 14 and 31)
with serologic evidence of HIV infection. Basic clinico-
pathologic features were shown in Table 2 and the sum-
maries were shown in Table 3.
Histopathologic, immunophenotypic, EBER in situ
hybridization, and T-cell receptor gene rearrangement
molecular studies
Results of immunophenotype, EBER in situ hybridization
and TCR gene rearrangement of the studied cases were
shown in Table 2. The summary of immunophenotypic
features were demonstrated in Table 4. In addition to
Table 1 List of PCR primers used for EBV subtyping and detection of LMP1 gene deletion
Type of Primer DNA sequence Product size
EBNA2 EBV type A 2A-5’ 5’-AACTTCAACCCACACCATCA-3’ 116 bp
EBV type B 2A-3’ 5’-TTCTGGACTATCTGGATCAT-3’ 120 bp
EBV LMP-1 wild-type 1-A 5’-CGACTCTGCTGGAAATGATGGAGGC-3’ 210 bp
deletion-type 1-B 5’-TGAACTGGGCCGTGGGGGTCGTCAT-3’ 180 bp
b-actin (semi-nested PCR) 1
st forward SFW 5’-CAAGAGATGGCCACGGCTGCT-3’
2
nd forward S4FW 5’-GAGGCACTCTTCCAGCCTTCC-3’ 148 bp
reverse A5RV 5’-TCGTGGATGCCACAGGACTCC-3’
EBNA2, Epstein-Barr virus nuclear antigen 2 gene; LMP1, latent membrane protein 1 gene
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Page 3 of 11Table 2 Clinical information, morphology, immunophenotype, EBER in situ hybridization, and TCR gene rearrangement of extranodal NK/T-cell lymphoma, nasal
type of head and neck region*
No. Age/
Sex
Site (s) of involvement Symptom (s) and its
duration
Basic morphology CD3 CD5 CD7 CD4 CD8 bF1 CD56 TIA1 GB PF CD45 CD30 EBER TCR
gene
Clinical
course
1 74/M Nasal cavity Rhinorrhea, 1 year large (A+, N+) + - - - - - + + + + + + + I D, 3 mos
2 40/M Nasal cavity Nasal obstruction, 3 mos medium (A+, N+) p+ - - - - - - + p+ p
+
- + + I D, 33 mos
3 31/M Nasal cavity Nasal obstruction, 1 mo large (A+, N+) p+ - - - - - + + + + + + + - D, 37 mos
4 37/M Nasal cavity Orbital cellulitis, and fever, 2
mos
medium (A-, N+) p+ - - - - - p- + p+ + NA + + - D, 3 mos
5 41/F Nasal cavity Nasal obstruction, 1 mo small to medium (A+,
N+)
+ - NA - - - + + p+ + + NA + - D, 3 mos
6 49/F Nasal cavity Nasal obstruction, 2 mos medium to large (A-,
N+)
+ - + - - - + + + + + p+ + - A, 60 mos
7 43/F Nasal cavity Nasal obstruction, 2 mos medium to large (A+,
N+)
p+ - - p+ - - + + + + - p+ + - D, 8 mos
8 32/M Nasal cavity Nasal obstruction, 5 mos medium to large (A-,
N+)
+-p ----++ p + p
+
NA - + - D, 3 mos
9 33/M Nasal cavity Rhinorrhea, 1 mo medium (A+, N+) + - + - - - + + p- p- p+ + + - D, 4 mos
10 38/M Nasal cavity Nasal obstruction with
epistaxis, 2 yrs
medium (A+, N+) + - - - - - p+ + + + + + + I D, 7 mos
11 48/F Nasal and oral cavities Nasal obstruction, 1 mos medium to large (A+,
N+)
+p + N A- - - p + +p + p
+
NA - + - D, 3 mos
12 36/M Nasal cavity and
nasopharynx
Epistaxis with fever, 1 mo small to medium (A+,
N+)
+ - + - - - + + p+ p- p+ - + - D, 1 mos
13 26/F Nasal cavity and
nasopharynx
Rhinorrhea, 2 mos medium (A+, N+) + p+ + - - - + + + + NA - + - D, 4 mos
14 42/M Nasal cavity and
nasopharynx
Epistaxis (HIV+), 2 mos medium to large (A-,
N+)
+ - - p+ - - + + + + p+ p+ + - D, 18 mos
15 41/M Nasopharynx Dysphagia, 3 mos medium (A+, N-) + - - - - - p+ + + + + + + - D, 11 mos
16 44/M Nasopharynx Rhinorrhea with epistaxis, 6
mos
medium to large (A+,
N+)
- - - - - - - + p+ - - + + - D, 2 mos
17 42/M Nasopharynx Nasal obstruction, 1 wk medium to large (A+,
N+)
+ - + - - - + + + + p+ + + I D, 5 mos
18 57/F Oral cavity Palatal mass, 2 mos large (A+, N+) + - - - - - + + + + p+ - + - D, 4 mos
19 38/M Oral cavity Chronic oral ulcer, 3 mos medium to large (A-,
N+)
+----- - + + p
+
+ p+ + - D, 3 mos
20 73/M Base of tongue and
larynx
Dysphagia, 2 mos medium to large (A+,
N+)
p+ - NA - - - + + + + p+ NA + - D, 6 mos
21 66/M Periorbital soft tissue Orbital cellulitis, 2 wks medium to large (A+,
N+)
- - p+ - - - + + + + p+ + + - D, 3 mos
22 56/M Periorbital soft tissue Blurred vision and headache, 2
mos
medium to large (A+,
N+)
+-- p + --++ p + p
+
+ p+ + - D, 10 mos
* Please see the abbreviations below
For “basic morphology": Large: predominantly (>75%) large cells; Medium to large: mixture of medium-sized to large cells (≥25% each); Medium: predominantly (>75%) medium-sized cells; Small to medium: mixture of
small to medium-sized cells (≥25% each); A+: presence of angioinvasion; A-: absence of angioinvasion; N+: presence of tissue necrosis; N-: absence of tissue necrosis
For immunophenotype: GB: granzyme B; PF: perforin; + (mostly positive): positive on lymphoma cells >50%; p+ (partially positive): 10-50% positive; p- (probably negative): <10% staining; - (negative): clearly negative; NA:
not available
For TCR gene (PCR -based TCR gene rearrangement analysis); - (negative): no clonal band on polyacrylamide gel electrophoresis and no dominant peak on fluorescence capillary electrophoresis; I: inadequate DNA quality
for PCR
For clinical course: A: alive; D: death
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1the results in Table 4, all tested cases were negative for
CD1a (19 cases), CD10 (17 cases), CD15 (21 cases),
CD57 (20 cases), CD23 (16 cases), CD34 (22 cases),
CD79a (18 cases), CD117 (16 cases), CD138 (18 cases),
TdT (18 cases), cyclin D1 (22 cases), PAX5 (22 cases),
BOB.1 (17 cases), BCL2 (18 cases), and BCL6 (18 cases).
PCR analysis for EBV subtype and LMP-1 deletion
After DNA extraction from FFPE tissue and DNA
amplification, 18 of 22 cases (82%) had adequate DNA
to perform TCR gene rearrangement analysis. All tested
cases showed negative results on both gel and fluores-
cence capillary electrophoresis (see Table 2).
For EBV subtyping and LMP-1 gene deletion, 15 of 22
cases had adequate tissue for these studies. All of the15
cases were determined as EBV subtype A and 13 of 15
cases (87%) had LMP-1 gene deletion type, while the
other 2 cases (13%) had wild type.
Clinical course
Of the 22 cases, patients with stage I, II and IV, were 13
(62%), 1 (5%) and 7 cases (33%), respectively. Among 29
cases, there were 2 cases (7%) with bone marrow invol-
v e m e n ta tt h et i m eo fd i a g n o s i s .O ft h e1 8c a s e sw i t h
available information, patients with IPI score of 0, 1, 2,
3 and 4, were 7 (39%), 3 (17%), 3 (17%), 3 (17%) and 2
cases (11%). Nineteen of the 22 cases (86%) were treated
with only chemotherapy, while 3 cases (no. 2, 3 and 8)
were treated with combined chemoradiotherapy.
Of the 22 cases, all patients but one died with a med-
ian survival of 4 months. The only survived patient who
had stage I disease and received only chemotherapy had
been followed up for 5 years. Adverse prognostic factors
included high Ann Arbor stage (stage IV vs. stage I or
II, survival of 3 vs. 7 months, p = 0.015), higher IPI
score (IPI score ≥1 vs. 0, 3 vs. 10 months, p = 0.003),
a n dl a c ko fp e r f o r i ne x p r e s s i o n( w i t h o u tv s .w i t hp e r -
forin expression, 2 vs. 4 months, p = 0.008). While the
expression of other markers including CD45, CD30,
CD7, Oct2 and IRF4/MUM1 failed to show any signifi-
cant difference in survival outcome.
Discussion
ENKTL has a significant higher incidence in Asian and
Latin American countries than the Western [1,2,24].
From the published series of 1983 cases of malignant
lymphoma from Thailand, T-cell lymphoma accounted
for 23% among overall new lymphoma cases [25], but
the frequency of ENKTL was not reported due to the
lack of markers for making a definite diagnosis. How-
ever, there were 69 cases of the so-called “angiocentric
lymphoma” in the REAL classification, a predecessor of
ENKTL, among the 381 cases of mature T-cell lym-
phoma in the series, thus the frequency of angiocentric
lymphoma was approximately 18% of mature T-cell
lymphoma, the second most common mature T- and
NK-cell lymphoma after PTCL, NOS, according to the
previous version of WHO classification (2001) [25]. A
recently published article from Thailand showed
ENKTL as the most common among the mature T- and
NK-cell lymphomas [4], accounting for 31%, which is
comparable to Taiwan (26%), Korea (37%) and Hong
Kong (39%) [26-28], but it is more common when com-
pared to China (up to 4.7%) [29], Japan (6%) [30] and
India (8%) [31]. The difference of ENKTL proportion
between Thailand and India may be due to the differ-
ence in the ethnic origin. In most parts of Japan,
Table 3 Summary of basic clinico-pathological features of
extranodal NK/T-cell lymphoma, nasal type of head and
neck region
Demographic data (From 31 cases) Frequency %
Age
- Range: 15-74 years
- Median: 42 years
- Mean: 45 years (SD 13)
Sex
- Male 23 74
- Female 8 26
- M/F ratio: 2.9
Major presenting clinical symptoms* (From 31
cases)
Frequency %
Nasal obstruction 15 48
Rhinorrhea 4 13
Epistaxis 4 13
Fever 3 10
Dysphagia 3 10
Orbital swelling and pain 2 7
Blurred vision and headache 1 3
Epiphora 1 3
Chronic oral ulcer 1 3
Palatal mass 1 3
Morphologic patterns (From 22 cases) Frequency %
Lymphoma cell size
- Predominantly small 0 0
- Mixed small and medium-sized 2 9
- Predominantly medium-sized 6 27
- Mixed medium-sized and large 11 50
- Predominantly large 3 17
- Anaplastic 0 0
Angioinvasion
- Present 15 68
- Not identified 7 32
Tissue necrosis
- Present 21 95
- Not identified 1 5
* Some cases have more than one major presenting symptom
Pongpruttipan et al. Diagnostic Pathology 2011, 6:79
http://www.diagnosticpathology.org/content/6/1/79
Page 5 of 11proportion of ENKTL is not high, but it is the second
most common mature T- and NK-cell lymphoma in
Okinawa; and if exclude cases of adult T-cell lym-
phoma/leukemia that is ultimately higher than other
countries, ENKTL proportion in this region will be 34%
and seems to be comparable to Thailand, Taiwan, Korea
and Hongkong [30]. The reasons for a lower ENKTL
proportion in most parts of Japan and mainland China
are not known.
In the study period of the present study, besides the
31 ENKTL cases, there was only one extranodal EBV-
n e g a t i v eT - c e l ll y m p h o m ai d e n t i f i e df r o mh e a da n d
neck region. It was a PTCL, NOS, involving nasophar-
ynx, and was positive for CD3, CD4, CD5, TIA-1, bF1,
but negative for CD8, CD20, CD56, CD30 and ALK.
Unfortunately, TCR gene rearrangement could not be
testified in this case due to the inadequate extracted
DNA.
E N K T Li nt h ep r e s e n ts t u d ys h o w e das t r o n gm a l e
predilection with male to female ratio of 2.9, similar to
the other previous reports [5,24]. In the present study,
the most common presenting symptom was nasal
obstruction, similar to the other previous reports [5,24].
The most common site of involvement was nasal cavity
while the second most common site was nasopharynx.
Nearly 84% of the cases (26/31) involved nasal cavity
and/or nasopharynx. In Thailand, a previous study
showed that ENKTL was the most common lymphoma
in nasal and paranasal sinuses while it might be less
common than diffuse large B-cell lymphoma in naso-
p h a r y n x[ 3 2 ] .I nt h ep r e s e n ts t u d y ,2o f3 1c a s e s( 7 % )
had periorbital soft tissue involvement; both cases
showed periorbital soft tissue involvement together with
mild haziness of paranasal sinuses demonstrated by CT
scan, while no lesion was observed from endoscopic
examination. Unfortunately, no pathologic sample was
sent for proving the occurrence of nasal disease. Thus,
it is not possible to conclude whether these 2 cases had
concomitant paranasal sinus involvement or they were a
genuine primary orbital lesion which was rarely reported
[33].
ENKTL with bone marrow involvement at presenta-
tion is rare. There were 2 out of 29 cases (7%) in the
present study, similar to other series [16,24,34,35]. In
particular cases with obvious marrow involvement, dis-
tinction between an aggressive NK-cell leukemia and a
leukemic phase of ENKTL should be problematic [1]. A
presence of nasal or nasopharygeal lymphoma would be
favored for ENKTL.
The present study demonstrated a high proportion of
cases with necrosis, similar to most other studies, while
evidence of angioinvasion varied [16,34,36]. The varied
proportion of necrosis among these studies presumably
depends on tissue sampling whether necrotic area was
Table 4 Summary of immunohistochemical results of the 22 cases of extranodal NK/T-cell lymphoma, nasal type
Marker Total cases Mostly positive Partially positive Overall positivity Probably negative Clearly negative Overall negativity
CD3 22 15 (68%) 5 (23%) 20 (91%) 0 2 (9%) 2( 9 %)
CD20 22 00 0 0 22 (100%) 22 (100%)
CD5 22 0 2 (9%) 2( 9 %) 0 20 (91%) 20 (91%)
CD7 19 5 (26%) 1 (5%) 6 (32%) 1 (5%) 12 (63%) 13 (68%)
CD4 22 0 3 (14%) 3 (14%) 0 19 (86%) 19 (86%)
CD8 22 00 0 0 22 (100%) 22 (100%)
bF1 22 00 0 0 22 (100%) 22 (100%)
CD56 22 15 (68%) 3 (14%) 18 (82%) 1 (5%) 3 (14%) 4 (18%)
CD57 21 00 0 0 21 (100%) 21 (100%)
TIA-1 22 22 (100%) 0 22 (100%) 0 0 0
Granzyme B 22 13 (59%) 8 (36%) 21 (95%) 1 (5%) 0 1( 5 %)
Perforin 22 14 (64%) 5 (23%) 19 (86%) 2 (9%) 1 (5%) 3 (14%)
CD45 18 8 (44%) 7 (39%) 15 (83%) 0 3 (17%) 3 (17%)
CD43 22 20 (91%) 2 (9%) 22 (100%) 0 0 0
CD30 20 10 (50%) 5 (25%) 15 (75%) 0 5 (25%) 5 (25%)
ALK 18 00 0 0 18 (100%) 18 (100%)
OCT2 20 1 (5%) 4 (20%) 5 (25%) 3 (15%) 12 (60%) 15 (75%)
IRF4/MUM1 15 1 (7%) 4 (27%) 5 (33%) 0 10 (67%) 10 (67%)
Mostly positive = definitely positive on lymphoma cells >50%
Partially positive = 10-50% positive staining
Overall positive = sum of mostly and partially positive results
Probably negative = <10% staining on presumptive lymphoma cells
Clearly negative = clearly negative
Overall negative = sum of probably negative and clearly negative results
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tion of angioinvasion, it could be resulted from either a
subjective determination by pathologists or from the
amount of tissue obtained for evaluation.
Cytological aspects of ENKTL varied from series to
series. In the present study, most cases (77%, 17/22
cases) had predominantly medium-sized cells or mixed
medium-sized and large cells. The lymphoma with med-
ium-sized cells commonly showed oval irregular nuclei
with occasional nuclear elongation, inconspicuous
nucleoli. Cases with large number of small cells might
be difficult to distinguish from reactive processes, as a
case found in the present study had been misdiagnosed
as fungal infection in the first biopsy. In this situation,
even presence of necrosis and fungi in the nasal cavity,
making diagnosis of fungal infection without careful eva-
luation of the lymphoid component was dangerous.
Thus, careful evaluation of lymphoid cells along with
immunohistochemistry and EBER in situ hybridization
might be helpful for making a diagnosis of lymphoma.
In our experience, a few cases showing monotonous
small lymphoma cells or anaplastic morphology were
also observed, but they were not in the study period;
such cases are uncommon as described in the WHO
classification blue book [5].
An advantage of TMA technique, other than cost and
time effectiveness, is that the tissue samples can act as
multiple controls within a single slide. The relatively
small tissue did not affect the interpretation much, since
most samples were from small cup biopsies. According
to the TMA technique, most of the cases in the present
study had typical ENKTL immunophenotype but with
minor differences to other series. The details were dis-
cussed below.
For the T-cell markers, CD3 is a highly sensitive mar-
ker and helpful for diagnosing ENKTL. However, CD3-
negative ENKTL were account for 9% (2/22 cases) in
the present study, which were also previously documen-
ted from other series [6,15,37]. Thus, negative for CD3
does not rule out ENKTL. For other T-cell markers,
CD5 is negative in almost all ENKTL, similar to pre-
vious study [5]. The present study had only 2 partially
CD5-positive cases. This could be resulted from CD5 on
reactive T-cells which sometime difficult to distin-
guished from neoplastic cells. Since there was no any
case with expression of b TCR protein as well as the
absence of demonstrable TCR gene rearrangement,
these results probably reflect that at least almost all
cases were genuine NK-cell in origin. However, we did
not have antibodies react with g or δ TCR to determine
whether they were gδ T-cell derived ENKTL which they
might have similar basic immunophenotype to that of
the NK-cell derived ENKTL. In contrast to CD5, CD7 is
normally expressed by normal NK-cells, but the present
study demonstrated that most of ENKTL (68%) lack
CD7 expression, which is similar to the previous studies
[29,38]. For CD43, even though it is a highly sensitive
marker for ENKTL, as demonstrated in the present
study as well as in other series [7,18], it is less useful for
subclassifying of T- and NK-cell neoplasms. For CD4,
we found a few cases (14%) with some staining as desig-
nated as partially positive. However, in these cases, dis-
tinction from CD4 expression by the admixed reactive
histiocytic and dendritic cells might be difficult. For
CD8, there was no positive case in the present series.
However, a previous study demonstrated up to 22% (9/
41 cases) of CD8-positive ENKTL which those cases
were also positive for CD56, but only 2 of 8 cases had
clonally rearranged PCR-based TCRg gene [36].
CD56 is a very helpful marker for diagnosing of
ENKTL, especially for distinguishing from reactive pro-
cesses which usually have only rare or a few scattered
CD56-positive small cells. The present study demon-
strated a high sensitivity of CD56 immunohistochemical
staining as 82% (18/22 cases), comparable to some pre-
vious studies such as 74% (31/42 cases) by Ng et al and
82% (37/45 cases) by Ko et al [34,36]. Higher CD56 sen-
sitivity has also been reported such as 97% (36/37 cases)
by Barrionuevo et al [16] and 100% (22/22 cases) by
Kuo et al [35]. Interestingly, a study using flow cyto-
metric immunophenotyping demonstrated all ENKTL
cases expressed CD56 [39]. Furthermore, a study on fro-
zen section immunohistochemistry also demonstrated
all cases of ENKTL had CD56 expression [40]. Hypothe-
tically, the variation in detection of CD56 expression
possibly reflects false negative results from immunohis-
tochemical technique performed on FFPE tissue, since
this technique might not be able to detect the cases
with weak CD56 expression. In addition, durability of
CD56 antigen in tissue, sensitivity of antibody clones,
and staining techniques should be considered to
improve the immunophenotypic results.
For the cytotoxic granules, as shown in Table 2 and 4,
TIA-1 is the most sensitive cytotoxic protein in ENKTL,
which some other studies also demonstrated 100% sensi-
tivity of TIA-1 expression [18,35,36,41]. On the other
hand, some studies showed the lacking of TIA-1 expres-
sion in a few cases [34,37]. In some series, granzyme B
was expressed in all cases tested [18,42]. In addition to
the highest sensitivity of TIA-1, it also was the most
intense staining when compared to granzyme B and
especially to perforin, based on the present study. Per-
forin is the least sensitive cytotoxic marker has also
been reported [18]. In term of lymphoid biology, since
both granzyme B and CD30 were considered as acti-
vated-cell markers [43,44], and they were found to be
positive in most cases. These results support an acti-
vated NK-cell phenotype of ENKTL, as it is believed.
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also demonstrated that ENKTL appeared to have a simi-
lar expression profile to activated NK-cell rather than a
normal non-activated one [45].
CD30 was positive in 75% (15/20 cases) of cases in the
present study, higher than other previous studies such
as 48% (13/27) by Ko et al and 41% (9/22) by Kuo et al
[34,35]. When compared to the CD30-negative cases,
there was no significant correlation of CD30 with other
immunostaining, patient’s age or site of involvement.
Cautiously, it is a potential difficulty for distinguishing
between CD56-, CD30+ ENKTL and CD56+ anaplastic
large cell lymphoma (ALCL), since 15% of ALCLs can
be positive for CD56 [46]. In this situation, presence or
absence of EBV or ALK protein may be helpful for mak-
ing a definite diagnosis.
CD45 (leukocyte common antigen) was not expressed
by some ENKTL in the present series. And this should
not be confused with a non-hematologic malignancy. To
the best of our knowledge, loss of this marker on paraf-
fin-section immunohistochemistry has never been
reported.
For B-cell markers, CD20, CD79a, PAX5 and BOB.1
were generally negative. Interestingly, some cases were
positive for Oct2, most of them showed focal and weak
positivity, however, a case with diffusely- and strongly-
positive lymphoma cells was documented. The expres-
sion of Oct2 in 1/2 ENKTL as well as some other types
of T-cell lymphomas was previously reported by Saez et
al [47]. But its significance is not known. Therefore,
study in more cases as well as in biologic detail might
be of interest.
IRF4/MUM1 is normally expressed in melonocytes,
plasma cells, B-cells and activated T-cells [48]. Besides
its expression in B-cell neoplasms, a variable IRF4/
MUM1 expression in systemic and cutaneous T-cell
lymphoproliferative disorders was reported [49]. The
IRF4/MUM1 expression has also been reported in 1 of 3
ENKTL by Natkunam et al [50]. While more recent stu-
dies from other regions of the world did not evaluate
IRF4/MUM1 expression in their case series [3,15]. The
significance of IRF4/MUM1 expression is not known,
and might be considered for further study in the future.
Of the 18 cases with PCR-based TCR gene rearrange-
ment study, which using BIOMED-2 primer design,
none of them showed positive result from both gel and
capillary fluorescence electrophoresis, which similar to
some previous studies [37,51,52]. On the other hand,
some studies using PCR-based techniques, demonstrated
TCR-gene rearranged ENKTL in a variable proportion,
such as 8% (1/12 cases) by Gaal et al [18], 9% (7/74) by
Gualco et al [15], 10% (3/31) by Ko et al [34], 27% (11/
41) by Ng et al [36], 30% (3/10) by Lin et al [53], and
up to 71% (10/14) by Mitarnun et al [54]. The varied
results of PCR-based TCR gene rearrangement among
these studies could be caused by the differences in tech-
niques and designed primers. While using Southern blot
analysis, the gold standard for TCR gene rearrangement
analysis, Suzumiya et al demonstrated rearrangement
only in 8% (1/13) of cases, but with the same technique,
Nakamura et al failed to demonstrate rearrangement in
all their 6 cases [6,7].
For the specificity of PCR-based TCR gene rearrange-
ment, it is noteworthy to emphasize that positive results
can also be found in a significant proportion of B-cell
lymphomas [55,56], acute non-lymphoid leukemia [57],
and even in reactive lymphoid tissues [58]. Thus, cases
with positive PCR-based TCR gene rearrangement
should not be always indicated as a T-cell lineage.
Interestingly, a study revealed genuine gδ T-cell lines
of nasal ENKTL, verified by demonstration of surface gδ
TCR by flow cytometry and immunophenotypic studies,
and was also positive for TCR gene rearrangement [59].
Such cases may be responsible for some ENKTL with
rearranged TCR gene, together with a few cases of com-
monly known ab-TCR-positive ENKTL. However,
methods for g-o rδ- TCR staining for demonstration of
gδ T-cell origin were not available in the present study.
EBV subtype A was noted from all tested cases (15
cases). As far as we know, the present study is the first
to demonstrate EBV subtype of ENKTL in Thailand.
The high prevalence of this subtype is similar to those
reports from East and Southeast Asia [2,5,6,10-12]. In
the non-Asian countries, while subtype B was found in
the majority of ENKTL in Peru, USA, and Germany
[13,16,18], but subtype A was predominant in Mexico,
Chile, Brazil, and Spain [14,15,17,19]. Furthermore,
Gualco et al recently described the striking differences
of EBV subtype among geographic regions in Brazil
which may reflect the heterogeneity of the ancestral
population [15].
In the present study, 87% of cases were found to be
the deletion type of EBV LMP-1 genes, similar to other
studies [5,6,12,35]. Since LMP-1 protein on EBV-positive
lymphoid cells is an antigenic target for cytotoxic T-
cells, high frequency of the deletion-type in ENKTL
compared to reactive conditions which wild-type are
more common, might suggest a clonal selection of
immunologically escapable EBV-infected cells in neo-
plastic processes [12].
The present study also demonstrated a highly aggres-
sive clinical course of ENKTL which was widely known.
Upfront radiotherapy was proved by recently published
studies to improve the survival outcome [5,8]. However,
most of the patients in this series received only che-
motherapy, and there were too few patients received
combined chemo-radiation therapy to do a statistic
comparison with.
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survival outcome in cases without perforin expression.
The cause of aggressive behavior is not known, but loss
of perforin expression possibly reflects the more com-
plex genetic abnormality in the tumor cells.
Conclusions
In conclusion, ENKTL is a distinctive T-/NK-cell lym-
phoma characterized by tissue necrosis, frequent
angioinvasion, EBV association, expression of cytotoxic
molecule (TIA-1), cytoplasmic CD3, and CD56 but lack-
ing CD5. Interestingly, losses of CD45 and CD7 were
not uncommon. Furthermore, Oct2 and IRF4/MUM1
expression could also be found in ENKTL. As ENKTL
needs a different therapeutic approach, any abnormal
lymphoid proliferation at upper aerodigestive tract
should be highly concerned for ENKTL. The diagnosis
should be relied on morphology, immunophenotype and
EBER in situ hybridization. However, based on the pre-
sent study conjunction with literature review, determi-
nation of TCR gene rearrangement by PCR-based
analysis may not be useful for making diagnosis of
ENKTL.
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